COMMUNIQUÉS West-GlobeNewswire

PharmAla Biotech Launches Phenesafe AI Drug Discovery Platform for Novel Phenethylamines
15/05/2025
TORONTO, May 15, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of [...]
Resmed Champions Sleep Health as The Official Sleep Partner of The Qatar Airways British & Irish Lions Tour to Australia 2025
15/05/2025
SAN DIEGO and LONDON and DUBLIN and SYDNEY, May 15, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, has been [...]
Intelligent Bio Solutions Accelerates Global Adoption of Fingerprint Drug Testing
15/05/2025
Company surpasses 450 accounts across 24 countries as global demand for fingerprint drug testing surges NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company [...]
Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting
15/05/2025
Statistically significant safety and efficacy data from 0.25 mg and 0.50 mg cohorts to be presented Presentation scheduled for Thursday, May 15, 2025, at 11:36 a.m. PT PITTSBURGH, May 15, 2025 (GLOBE NEWSWIRE) -- [...]
GT Biopharma Appoints New Member to its Board of Directors
15/05/2025
SAN FRANCISCO, CALIFORNIA, May 15, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company' [...]
Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update
15/05/2025
Initiated Phase 2 Seabreeze STAT Asthma and Seabreeze STAT COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations in Asthma and COPD in May 2025; topline data expected in 1H 2026 Published [...]
OmniMD Announces AI Clinicians: Ushering in a New Era of Predictive, Personalized, and Effortless Healthcare Delivery
15/05/2025
OmniMD unveils AI Clinicians; a bold leap into the future of healthcare. Designed to think like a physician and act faster than one, AI Clinicians combine clinical intelligence, predictive analytics, and real-time [...]
Global Medtech Outsourcing Market Grows to $89B in 2024 as CDMOs Emerge as Strategic Partners, Finds Alira Health
15/05/2025
Fifth annual report reveals growing OEM reliance on CDMOs, M&A momentum, and innovation in polymers and orthopedics FRAMINGHAM, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Alira Health, a global healthcare consulting [...]
New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline
15/05/2025
NATALEE subanalysis evaluates Kisqali in pre-menopausal early breast cancer patients, amid rising diagnosis rates in younger patients Pluvicto analysis and Scemblix ASC4START primary endpoint results provide insights [...]
Medicines for Poland: Europe Faces a Critical Choice on Medicines and Market Reform
15/05/2025
WARSAW, Poland, May 15, 2025 (GLOBE NEWSWIRE) -- Member States are nearing the end of discussions on EU pharmaceutical reform to ensure affordable medicines and support EU manufacturing in Europe. This will enhance the [...]
Xenon MRI Featured Prominently at ATS 2025 Across Broad Clinical Spectrum
15/05/2025
30+ studies across diverse conditions illuminate the unique value of functional lung imaging with Xenon MRI DURHAM, NC and LONDON, May 15, 2025 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX) (“Polarean” or the “ [...]
SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML
15/05/2025
- First ASXL1 Pediatric Acute Myeloid Leukemia (AML) Patient Dosed at MD Anderson Cancer Center: Program Supported by Rare Pediatric Disease Designation (RPDD) NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- SELLAS Life [...]
GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025
15/05/2025
Positive interim 2-week safety and biomarker results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (“IPF”) Continued momentum with completed patient enrollment [...]
Veri Medtech (VRHI) Reaches $100 Million Revenue Milestone
15/05/2025
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Veri Medtech Holdings, Inc. (Stock Ticker Symbol: “ VRHI ”) ("Veri Medtech"), healthcare technology platform, announced today that $3,308,297 in revenue was generated during [...]
CytoDyn Releases ESMO Breast Cancer Meeting Poster
15/05/2025
VANCOUVER, Washington, May 15, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple [...]
Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
15/05/2025
GLEN ALLEN, Va., May 15, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and [...]
Excision BioTherapeutics Announces Publication Highlighting EBT-107 for the Treatment of Chronic Hepatitis B in bioRxiv
15/05/2025
Treatment with EBT-107 led to a rapid reduction in clinical biomarkers and suppression of random HBV DNA integration with minimal risk of treatment-related chromosomal aberrations Excision’s proprietary gene editing [...]
CorMedix Inc. to Participate in the RBC Global Healthcare Conference
15/05/2025
BERKELEY HEIGHTS, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and [...]
Sienna Announces May Dividend
15/05/2025
MARKHAM, Ontario, May 15, 2025 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “ Common Share ”) for [...]

Pages